Enanta Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: ENTA · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filing
Related Tickers: ENTA
TL;DR
Enanta's 8-K shows leadership changes and votes, filed March 17.
AI Summary
Enanta Pharmaceuticals, Inc. filed an 8-K on March 17, 2025, reporting events as of March 13, 2025. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in Enanta's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: low — The filing is routine and reports on standard corporate governance events without immediate financial implications.
Key Players & Entities
- Enanta Pharmaceuticals, Inc. (company) — Registrant
- March 13, 2025 (date) — Earliest event reported
- March 17, 2025 (date) — Date of report
FAQ
What specific officer or director departed from Enanta Pharmaceuticals?
The filing does not specify the names of any departing officers or directors, only that such events are reported under Item 5.02.
Were any new officers or directors elected or appointed?
Yes, the filing indicates the election of directors and appointment of certain officers under Item 5.02.
What type of compensatory arrangements were disclosed?
The filing mentions compensatory arrangements of certain officers under Item 5.02, but the details are not provided in this summary.
Were any matters submitted to a vote of security holders?
Yes, the filing confirms the submission of matters to a vote of security holders under Item 5.07.
What financial information is included in this filing?
The filing includes financial statements and exhibits as per Item 9.01.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding ENANTA PHARMACEUTICALS INC (ENTA).